Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
144 studies found for:    Hemophilia: Clinical Trials
Show Display Options
Rank Status Study
21 Completed A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia A With Inhibitors;   Haemophilia B;   Haemophilia B With Inhibitors
Intervention: Drug: eptacog alfa (activated)
22 Not yet recruiting Hemophilia Inhibitor Prevention (INHIBIT) Trial
Condition: Severe Hemophilia A
Intervention: Drug: Long-acting recombinant factor VIII Fc fusion protein
23 Terminated Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A
Condition: Hemophilia A
Interventions: Drug: Rituxan;   Drug: prednisone
24 Completed
Has Results
Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment
Condition: Hemophilia A
Intervention: Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
25 Recruiting A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa pegol
26 Completed Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
27 Completed
Has Results
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
Conditions: Blood Coagulation Disorders;   Hemophilia A
Interventions: Biological: Recombinant Factor VIII (BAY81-8973);   Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
28 Completed PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A
Condition: Hemophilia A
Intervention: Drug: Intravenous infusions of Xyntha
29 Completed Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Intervention: Drug: activated recombinant human factor VII, long acting
30 Completed Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Intervention: Drug: activated recombinant human factor VII
31 Completed Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration
Condition: Hemophilia A
Intervention: Biological: BAY94-9027 + Kogenate FS (Recombinant Factor VIII, BAY14-2222)
32 Completed
Has Results
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
33 Completed Trial of NovoSeven® in Haemophilia - Joint Bleeds
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Interventions: Drug: eptacog alfa (activated);   Drug: Feiba VH
34 Completed Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: nonacog beta pegol
35 Recruiting Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
Condition: Hemophilia A
Intervention: Drug: Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)
36 Active, not recruiting Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa pegol
37 Completed
Has Results
Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Interventions: Drug: eptacog alfa (activated);   Drug: vatreptacog alfa (activated)
38 Completed
Has Results
Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
39 Completed Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Interventions: Drug: Advate®;   Drug: turoctocog alfa
40 Recruiting Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A."
Condition: Hemophilia A
Intervention: Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.